碩世生物(688399.SH)漲停創上市新高 多次捐贈新冠病毒核酸檢測試劑及儀器
格隆匯2月3日丨碩世生物(688399.SH)漲20%封漲停板,報117.48元,創上市新高,暫成交4.96億元,最新總市值68.87億元。公司昨晚公告,鑑於武漢新型冠狀病毒引發的疫情蔓延,為了履行社會責任,支持疫情防控工作,擬向疾控系統及醫療機構捐贈累計價值1000萬人民幣新型冠狀病毒核酸檢測試劑及儀器,用於新型冠狀病毒以及其他冠狀病毒的檢測。1月27日,美年大健康產業聯合碩世生物向武漢市紅十字會、湖北省慈善總會捐出總計4.6萬人份的新型冠狀病毒(2019)核酸檢測試劑及儀器。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.